ArticlePLOS digital health2024
A statistical modelling approach for determining the cause of reported respiratory syndromes from internet-based participatory surveillance when influenza virus and SARS-CoV-2 are co-circulating.
Article in PLOS digital health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symptom-only case definitions are insufficient to discriminate COVID-like illness from acute respiratory infection (ARI) or influenza-like illness (ILI), due to the overlap in case definitions. Our objective was to develop a statistical method that does not rely on case definitions to determine the contribution of influenza virus and SARS-CoV-2 to the ARI burden during periods when both viruses are circulating. Data sources used for testing the approach were weekly ARI syndrome reports from the Infectieradar participatory syndromic surveillance system during the analysis period (the first 25 weeks of 2022, in which SARS-CoV-2 and influenza virus co-circulated in the Netherlands) and data from virologically tested ARI (including ILI) patients who consulted a general practitioner in the same period. Estimation of the proportions of ARI attributable to influenza virus, SARS-CoV-2, or another cause was framed as an inference problem, through which all data sources are combined within a Bayesian framework to infer the weekly numbers of ARI reports attributable to each cause. Posterior distributions for the attribution proportions were obtained using Markov Chain Monte-Carlo methods. Application of the approach to the example data sources indicated that, of the total ARI reports (total of 11,312; weekly mean of 452) during the analysis period, the model attributed 35.4% (95% CrI: 29.2-40.0%) and 27.0% (95% CrI: 19.3-35.2%) to influenza virus and SARS-CoV-2, respectively. The proposed statistical model allows the attribution of respiratory syndrome reports from participatory surveillance to either influenza virus or SARS-CoV-2 infection in periods when both viruses are circulating, but comparability of the participatory surveillance and virologically tested populations is important. Portability for use by other countries with established participatory respiratory surveillance systems is an asset.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.